| 1 |
Congly SE, Syed A, Haylock-jacobs S, Israelson H, Pinto J, Williams S, Lee SS, Coffin CS. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B. Canadian Liver Journal 2023. [DOI: 10.3138/canlivj-2022-0043] [Reference Citation Analysis]
|
| 2 |
Somé EN, Nana FW, Méda BI, Son M, Maxime D, Kouanda S, Sombié R. Chronic Carriage of Hepatitis B Virus at the University Teaching Hospital Yalgado Ouedraogo: Therapeutic Aspects and Outcome in a Cohort of HBeAg+ Outpatients. OJEpi 2021;11:245-255. [DOI: 10.4236/ojepi.2021.113021] [Reference Citation Analysis]
|
| 3 |
Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 4 |
Wigfield P, Sbarigia U, Hashim M, Vincken T, Heeg B. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. Pharmacoecon Open 2020;4:403-18. [PMID: 31428938 DOI: 10.1007/s41669-019-00175-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 5 |
Toy M, Hutton DW, So S. Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment. Curr Hepatology Rep 2019;18:357-62. [DOI: 10.1007/s11901-019-00482-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 6 |
Lau CI, Barbarulo A, Solanki A, Saldaña JI, Crompton T. The kinesin motor protein Kif7 is required for T-cell development and normal MHC expression on thymic epithelial cells (TEC) in the thymus. Oncotarget 2017;8:24163-76. [PMID: 28445929 DOI: 10.18632/oncotarget.15241] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Fang SY, Han H. Hepatitis E viral infection in solid organ transplant patients: . Current Opinion in Organ Transplantation 2017;22:351-5. [DOI: 10.1097/mot.0000000000000432] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 8 |
Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig 2017;37:233-47. [PMID: 27928739 DOI: 10.1007/s40261-016-0486-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 9 |
Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT. Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLoS Pathog 2016;12:e1005788. [PMID: 27487232 DOI: 10.1371/journal.ppat.1005788] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 10 |
Liu SH, Seto WK, Lai CL, Yuen MF. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Rev Gastroenterol Hepatol 2016;10:697-707. [PMID: 26799653 DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 11 |
Peg-IFN α-2a best first-line strategy in hepatitis B. PharmacoEcon Outcomes News 2015;738:24-24. [DOI: 10.1007/s40274-015-2506-y] [Reference Citation Analysis]
|
